The Tensin-3 Protein, Including its SH2 Domain, Is Phosphorylated by Src and Contributes to Tumorigenesis and Metastasis

Cancer Cell

Volumn 16, Issue 3, 2009, Pages 246-258

  Qian, Xiaolan ^a   Li, Guorong ^a   Vass, William C ^a   Papageorge, Alex ^a   Walker, Renard C ^a   Asnaghi, Laura ^a   Steinbach, Peter J ^b   Tosato, Giovanna ^a   Hunter, Kent ^a   Lowy, Douglas R ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

CELLBIO; CELLCYCLE; SIGNALING

Indexed keywords

CRK ASSOCIATED SUBSTRATE PROTEIN; FOCAL ADHESION KINASE 1; INTEGRIN LINKED KINASE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE SHP; SMALL INTERFERING RNA; TENSIN; TENSIN 3; TYROSINE; UNCLASSIFIED DRUG;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; BREAST CANCER; CARCINOGENESIS; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; ENZYME SUBSTRATE; HUMAN; HUMAN CELL; LIGAND BINDING; LUNG CANCER; MELANOMA; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED NOD; MICE, INBRED STRAINS; MICE, SCID; NEOPLASM METASTASIS; NEOPLASMS; PHOSPHOPROTEIN PHOSPHATASES; PHOSPHORYLATION; RNA, SMALL INTERFERING; SRC HOMOLOGY DOMAINS; TRANSFECTION;

EID: 69249241828     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.07.031     Document Type: Article

References (40)

1. Bergamo A., Masi A., Dyson P.J., and Sava G. Modulation of the metastatic progression of breast cancer with an organometallic ruthenium compound. Int. J. Oncol. 33 (2008) 1281-1289
2. Chen H., Duncan I.C., Bozorgchami H., and Lo S.H. Tensin1 and a previously undocumented family member, tensin2, positively regulate cell migration. Proc. Natl. Acad. Sci. USA 99 (2002) 733-738
3. Chen H., Ishii A., Wong W.K., Chen L.B., and Lo S.H. Molecular characterization of human tensin. Biochem. J. 351 (2000) 403-411
4. Chiang M.K., Liao Y.C., Kuwabara Y., and Lo S.H. Inactivation of tensin3 in mice results in growth retardation and postnatal lethality. Dev. Biol. 279 (2005) 368-377
5. Cho A.R., Uchio-Yamada K., Torigai T., Miyamoto T., Miyoshi I., Matsuda J., Kurosawa T., Kon Y., Asano A., Sasaki N., and Agui T. Deficiency of the tensin2 gene in the ICGN mouse: an animal model for congenital nephrotic syndrome. Mamm. Genome 17 (2006) 407-416
6. Cui Y., Liao Y.C., and Lo S.H. Epidermal growth factor modulates tyrosine phosphorylation of a novel tensin family member, tensin3. Mol. Cancer Res. 2 (2004) 225-232
7. Davis S., Lu M.L., Lo S.H., Lin S., Butler J.A., Druker B.J., Roberts T.M., An Q., and Chen L.B. Presence of an SH2 domain in the actin-binding protein tensin. Science 252 (1991) 712-715
8. Defilippi P., Di Stefano P., and Cabodi S. p130Cas: a versatile scaffold in signaling networks. Trends Cell Biol. 16 (2006) 257-263
9. Durkin M.E., Yuan B.Z., Zhou X., Zimonjic D.B., Lowy D.R., Thorgeirsson S.S., and Popescu N.C. DLC-1:a Rho GTPase-activating protein and tumour suppressor. J. Cell. Mol. Med. 11 (2007) 1185-1207
10. Giaccone G., and Zucali P.A. Src as a potential therapeutic target in non-small-cell lung cancer. Ann. Oncol. 19 (2008) 1219-1223
11. Guy C.T., Muthuswamy S.K., Cardiff R.D., Soriano P., and Muller W.J. Activation of the c-Src tyrosine kinase is required for the induction of mammary tumors in transgenic mice. Genes Dev. 8 (1994) 23-32
12. Hafizi S., Ibraimi F., and Dahlback B. C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. FASEB J. 19 (2005) 971-973
13. Healy K.D., Hodgson L., Kim T.Y., Shutes A., Maddileti S., Juliano R.L., Hahn K.M., Harden T.K., Bang Y.J., and Der C.J. DLC-1 suppresses non-small cell lung cancer growth and invasion by RhoGAP-dependent and independent mechanisms. Mol. Carcinog. 47 (2008) 326-337
14. Huang H., Li L., Wu C., Schibli D., Colwill K., Ma S., Li C., Roy P., Ho K., Songyang Z., et al. Defining the specificity space of the human SRC homology 2 domain. Mol. Cell. Proteomics 7 (2008) 768-784
15. Johnson F.M., and Gallick G.E. SRC family nonreceptor tyrosine kinases as molecular targets for cancer therapy. Anticancer. Agents Med. Chem. 7 (2007) 651-659
16. Katz M., Amit I., Citri A., Shay T., Carvalho S., Lavi S., Milanezi F., Lyass L., Amariglio N., Jacob-Hirsch J., et al. A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration. Nat. Cell Biol. 9 (2007) 961-969
17. Liao Y.C., Si L., Devere White R.W., and Lo S.H. The phosphotyrosine-independent interaction of DLC-1 and the SH2 domain of cten regulates focal adhesion localization and growth suppression activity of DLC-1. J. Cell Biol. 176 (2007) 43-49
18. Lindberg U., Karlsson R., Lassing I., Schutt C.E., and Hoglund A.S. The microfilament system and malignancy. Semin. Cancer Biol. 18 (2008) 2-11
19. Liu B.A., Jablonowski K., Raina M., Arce M., Pawson T., and Nash P.D. The human and mouse complement of SH2 domain proteins-establishing the boundaries of phosphotyrosine signaling. Mol. Cell 22 (2006) 851-868
20. Lo S.H. Tensin. Int. J. Biochem. Cell Biol. 36 (2004) 31-34
21. Lo S.H., and Lo T.B. Cten, a COOH-terminal tensin-like protein with prostate restricted expression, is down-regulated in prostate cancer. Cancer Res. 62 (2002) 4217-4221
22. Lo S.H., Yu Q.C., Degenstein L., Chen L.B., and Fuchs E. Progressive kidney degeneration in mice lacking tensin. J. Cell Biol. 136 (1997) 1349-1361
23. Lo S.S., and Lo S.H. Cleavage of cten by caspase-3 during apoptosis. Oncogene 24 (2005) 4311-4314
24. Machida K., and Mayer B.J. The SH2 domain: versatile signaling module and pharmaceutical target. Biochim. Biophys. Acta 1747 (2005) 1-25
25. Manning G., Whyte D.B., Martinez R., Hunter T., and Sudarsanam S. The protein kinase complement of the human genome. Science 298 (2002) 1912-1934
26. Martuszewska D., Ljungberg B., Johansson M., Landberg G., Oslakovic C., Dahlback B., and Hafizi S. Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer. PLoS ONE 4 (2009) e4350
27. Mitra S.K., and Schlaepfer D.D. Integrin-regulated FAK-Src signaling in normal and cancer cells. Curr. Opin. Cell Biol. 18 (2006) 516-523
28. Mitra S., Beach C., Feng G.S., and Plattner R. SHP-2 is a novel target of Abl kinases during cell proliferation. J. Cell Sci. 121 (2008) 3335-3346
29. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 16 (1983) 55-63
30. Nasertorabi F., Tars K., Becherer K., Kodandapani R., Liljas L., Vuori K., and Ely K.R. Molecular basis for regulation of Src by the docking protein p130Cas. J. Mol. Recognit. 19 (2006) 30-38
31. Parsons S.J., and Parsons J.T. Src family kinases, key regulators of signal transduction. Oncogene 23 (2004) 7906-7909
32. Plaumann M., Seitz S., Frege R., Estevez-Schwarz L., and Scherneck S. Analysis of DLC-1 expression in human breast cancer. J. Cancer Res. Clin. Oncol. 129 (2003) 349-354
33. Qian X., Li G., Asmussen H.K., Asnaghi L., Vass W.C., Braverman R., Yamada K.M., Popescu N.C., Papageorge A.G., and Lowy D.R. Oncogenic inhibition by a deleted in liver cancer gene requires cooperation between tensin binding and Rho-specific GTPase-activating protein activities. Proc. Natl. Acad. Sci. USA 104 (2007) 9012-9017
34. Smalley K.S., Haass N.K., Brafford P.A., Lioni M., Flaherty K.T., and Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5 (2006) 1136-1144
35. Torgler C.N., Narasimha M., Knox A.L., Zervas C.G., Vernon M.C., and Brown N.H. Tensin stabilizes integrin adhesive contacts in Drosophila. Dev. Cell 6 (2004) 357-369
36. Vogelstein B., and Kinzler K.W. Cancer genes and the pathways they control. Nat. Med. 10 (2004) 789-799
37. Yam J.W., Ko F.C., Chan C.Y., Jin D.Y., and Ng I.O. Interaction of deleted in liver cancer 1 with tensin2 in caveolae and implications in tumor suppression. Cancer Res. 66 (2006) 8367-8372
38. Yam J.W., Ko F.C., Chan C.Y., Yau T.O., Tung E.K., Leung T.H., Jin D.Y., and Ng I.O. Tensin2 variant 3 is associated with aggressive tumor behavior in human hepatocellular carcinoma. Hepatology 44 (2006) 881-890
39. Yuan B.Z., Jefferson A.M., Baldwin K.T., Thorgeirsson S.S., Popescu N.C., and Reynolds S.H. DLC-1 operates as a tumor suppressor gene in human non-small cell lung carcinomas. Oncogene 23 (2004) 1405-1411
40. Yuan B.Z., Zhou X., Durkin M.E., Zimonjic D.B., Gumundsdottir K., Eyfjord J.E., Thorgeirsson S.S., and Popescu N.C. DLC-1 gene inhibits human breast cancer cell growth and in vivo tumorigenicity. Oncogene 22 (2003) 445-450